Drug Trial Radar · NCT05922878
Study of ALTO-300 in MDD
Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
325
Planned (sponsor's estimate)
Start
Jun 8, 2023
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Alto NeuroscienceIndustry
- Sponsor type
- Industry
- First posted
- Jun 28, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.
Conditions
- Major Depressive Disorder
Interventions
ALTO-300Drug
ALTO-300 capsule QD
PlaceboDrug
Placebo capsule QD
Primary outcomes
What the sponsor says the trial is designed to measure.
- To assess efficacy of adjunctive ALTO-300 versus placebo on symptoms of MDD in a pre-defined subgroup of participants as measured by the change over time up to week 6 in the Montgomery-Åsberg Depression Rating Scale (MADRS).Time frame: Change over time for up to week 6
Locations
75 sites in 1 country. Site status is shown where the registry gives one.
Site 200
Phoenix, Arizona · Recruiting
Site 189
Phoenix, Arizona · Withdrawn
Site 187
Yuma, Arizona · Active not recruiting
Site 193
Rogers, Arkansas · Recruiting
Site 218
Bellflower, California · Recruiting
Site 318
Carlsbad, California · Active not recruiting
Site 217
Glendale, California · Active not recruiting
Site 335
Lafayette, California · Recruiting
Site 335
Lafayette, California · Recruiting
Site 209
Los Angeles, California · Active not recruiting
Site 219
Mather, California · Recruiting
Site 194
Mission Viejo, California · Terminated
Site 267
Moorpark, California · Recruiting
Site 197
Temecula, California · Recruiting
Site 203
Colorado Springs, Colorado · Active not recruiting
Site 343
Denver, Colorado · Recruiting
Site 345
Evergreen, Colorado · Active not recruiting
Site 349
Evergreen, Colorado · Active not recruiting
Site 214
Norwalk, Connecticut · Withdrawn
Site 159
Clermont, Florida · Terminated
Site 225
Miami Gardens, Florida · Active not recruiting
Site 190
Miami Lakes, Florida · Active not recruiting
Site 161
Okeechobee, Florida · Active not recruiting
Site 221
Tampa, Florida · Recruiting
Site 220
West Palm Beach, Florida · Active not recruiting
Site 238
Fayetteville, Georgia · Recruiting
Site 224
Savannah, Georgia · Active not recruiting
Site 208
Snellville, Georgia · Terminated
Site 293
Stone Mountain, Georgia · Not yet recruiting
Site 317
Blackfoot, Idaho · Withdrawn
Site 119
Boise, Idaho · Active not recruiting
Site 236
Boise, Idaho · Recruiting
Site 310
Chicago, Illinois · Active not recruiting
Site 314
Wichita, Kansas · Active not recruiting
Site 201
Marrero, Louisiana · Terminated
Site 198
Monroe, Louisiana · Terminated
Site 288
Worcester, Massachusetts · Recruiting
Site 240
Mankato, Minnesota · Recruiting
Site 265
Minneapolis, Minnesota · Recruiting
Site 279
Hattiesburg, Mississippi · Withdrawn
Showing 40 of 75 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.